SPC
PBE icon

Sigma Planning Corp’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Sigma Planning Corp’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,466
Closed -$202K – 732
2015
Q2 		$202K Buy
+3,466
New +$198K 0.03% 631

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return
QA
Quantitative Advantage Minnetonka, Minnesota $689M AUM 6.25% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sigma Planning Corp's PBE Position: Q3 2015 in Review

Sigma Planning Corp sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2015, closing a stake of 3,466 shares — an estimated $202K sold.

Sigma Planning Corp first reported a position in PBE in Q2 2015 and held it in 1 quarter. The position peaked at $202K in Q2 2015. 82 funds tracked by Wall St. Rank hold PBE as of Q3 2015.

  • Sigma Planning Corp reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2015 after selling out during the quarter.
  • Sigma Planning Corp sold 3,466 Invesco Biotechnology & Genome ETF shares in Q3 2015, an estimated $202K.
  • Sigma Planning Corp first reported a position in Invesco Biotechnology & Genome ETF in Q2 2015 and held it in 1 quarter.
  • Sigma Planning Corp's Invesco Biotechnology & Genome ETF position peaked at $202K in Q2 2015.
  • 82 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2015.

Based on Sigma Planning Corp's 13F filing for Q3 2015, filed 2 Nov 2015.